Drugs / Streptococcus salivarius K12
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05918224 | Jan → Nov 2022 | head and neck squamous cell carcinoma | West China Hospital | Completed | No outcome recorded |
| Phase 2 | NCT05175833 | Sep 2020 → Jan 2021 | COVID-19, bacterial pneumonia | Universidade de Passo Fundo | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Streptococcus salivarius K12 | “oral gel containing Streptococcus salivarius K12 (2 billion live bacilli) and Lactobacillus brevis CD2 (4 billion live bacilli)” NCT05175833 ↗ |
| Route | Oral | “Streptococcus salivarius K12 is dissolved in the mouth and then swallowed.” NCT05918224 ↗ |